Drug Approval | February 26, 2022
Japan approves Keytruda plus Lenvima for two types of cancer
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The facility is spread across 215000 sq. feet and provides super-speciality care
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Collaboration in the industry needs to be institutionalised to drive the growth.
Subscribe To Our Newsletter & Stay Updated
